|
|
||||||||
Published online before print May 3, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York
2Correspondence: Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021. E-mail: xim2002{at}med.cornell.edu
Interleukin-12 (IL-12)-mediated immune responses are critical for the control of malignant development. Tumors can actively resist detrimental immunity of the host via many routes. Prostaglandin E2 (PGE2) is one of the major immune-suppressive factors derived from many types of tumors. Here, we show that systemic administration of recombinant IL-12 could therapeutically control the growth of aggressive TS/A and 4T1 mouse mammary carcinomas. However, PGE2 produced by tumors potently inhibits the production of endogenous IL-12 at the level of protein secretion, mRNA synthesis, and transcription of the constituent p40 and p35 genes. The inhibition can be reversed by NS-398, a selective inhibitor of the enzymatic activity of cyclooxygenase 2 in PGE2 synthesis. Moreover, PGE2-mediated inhibition of IL-12 production requires the functional cooperation of AP-1 and AP-1 strongly suppresses IL-12 p40 transcription. Blocking PGE2 production in vivo results in a marked reduction in lung metastasis of 4T1 tumors, accompanied by enhanced ability of peritoneal macrophages to produce IL-12 and spleen lymphocytes to produce interferon-
. This study contributes to the elucidation of the molecular mechanisms underlying the interaction between a progressive malignancy and the immune defense apparatus.
Key Words: activated protein-1 cytotoxic T lymphocyte natural killer cells macrophage tumor immunity
This article has been cited by other articles:
![]() |
G. Natarajan, S. Ramalingam, I. Ramachandran, R. May, L. Queimado, C. W. Houchen, and S. Anant CUGBP2 downregulation by prostaglandin E2 protects colon cancer cells from radiation-induced mitotic catastrophe Am J Physiol Gastrointest Liver Physiol, May 1, 2008; 294(5): G1235 - G1244. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Hu, J. Chen, L. Wang, and L. B. Ivashkiv Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation J. Leukoc. Biol., August 1, 2007; 82(2): 237 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Franke, W. Lante, E. Kurig, L. G. Zoller, C. Weinhold, and A. Markewitz Is interferon gamma suppression after cardiac surgery caused by a decreased interleukin-12 synthesis? Ann. Thorac. Surg., July 1, 2006; 82(1): 103 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Lewis and J. W. Pollard Distinct Role of Macrophages in Different Tumor Microenvironments Cancer Res., January 15, 2006; 66(2): 605 - 612. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Shan, L. Chen, J. T. Njardarson, C. Gaul, X. Ma, S. J. Danishefsky, and X.-Y. Huang Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice PNAS, March 8, 2005; 102(10): 3772 - 3776. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |